Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. (NBIX) Stock Overview

Explore Neurocrine Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

NBIX●NASDAQ
HealthcareBiotechnology
$152.72
$1.90(1.26%)
U.S. Market opens in 47h 5m

Neurocrine Biosciences, Inc. (NBIX)

Meyka AI Score

Z

Key Financials

Market Cap15.4B
P/E Ratio21.59
EPS (TTM)$6.92
ROE0.21%
Fundamental Analysis

AI Price Forecasts

1 Month$179.32
3 Months$172.50
1 Year Target$159.97

NBIX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Neurocrine Biosciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of NBIX on the NASDAQ shows an RSI of 34.98, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $159.97 for the NASDAQ listing.

Key metrics behind Neurocrine Biosciences, Inc.'s NASDAQ-traded stock include a P/E ratio of 21.59 and a market capitalization of 15.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of NBIX on the NASDAQ.

Price Performance (NASDAQ: NBIX)

1-Day Change
1.26%
5-Day Change
-5.45%
1-Month Change
-11.23%
3-Month Change
-3.98%
6-Month Change
23.04%
Year-to-Date (YTD) Change
7.68%
1-Year Change
16.30%
3-Year Change
44.68%
5-Year Change
69.35%
All-Time (Max) Change
1121.76%

Contact Information

https://www.neurocrine.com
858 617 7600
6027 Edgewood Bend Court, San Diego, CA, 92130

Company Facts

25,000 Employees
IPO DateMay 23, 1996
CountryUS
Actively Trading

Frequently Asked Questions